Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ISET 25: Drug Delivery Devices: Paclitaxel Drug-Coated Balloons and Drug-Eluting Stents
Author(s): Marianne Brodmann Added: 1 year ago
ISET 2025 - How have drug delivery devices changed over the years, and what are the novel technologies and therapeutic agents?Dr Marianne Brodmann (Medical University of Graz, AT) joins us onsite at ISET 2025 to discuss the current landscape of drug delivery devices, from paclitaxel drug-coated balloons to drug-eluting stents. Dr Brodmann discusses evolving technologies, including bioresorbable… View more

Intervention

Vascular Disease and Surgery
Drug-coated Balloon Angioplasty in Sri Lanka
Author(s): Yanushka Herath , Judy Ranaweera , Thisal Semina , et al Added: 2 months ago

Intervention

Prevention & Chronic Conditions
TCT 2025: SELUTION DeNovo: 1-Year Results Comparing Sirolimus Balloon vs DES in PCI
Author(s): Christian Spaulding Added: 3 months ago
TCT 2025 — Prof Christian M Spaulding (European Hospital Georges Pompidou & INSERM U 970, FR), principal investigator of the SELUTION DeNovo trial (M.A. Med Alliance S.A.; NCT04859985), joins us to share the one year results.This international, multicentre randomised trial enrolled over 3,300 patients at 50 sites across Europe and Asia to compare a sirolimus-eluting balloon (SEB) plus provisional… View more

Intervention
TCT 24: The ECLIPSE Trial
Author(s): Ajay J Kirtane Added: 1 year ago
TCT Conference 2024 - Routine use of orbital atherectomy system (OAS) did not improve minimal stent area (MSA) or target vessel failure (TVF) at one year compaared to conventional balloon angioplasty.Dr Ajay J Kirtane (Columbia University Medical Center and New York-Presbyterian Hospital, New York, US) joins us onsite at TCT Conference to discuss the findings from ECLIPSE (NCT03108456; Abbott… View more

Intervention
TCT 24: Sirolimus- vs. Paclitaxel-Coated Balloon Angioplasty
Author(s): Ulf Teichgräber Added: 1 year ago
TCT Conference 2024 - Safety and efficacy outcomes of the trial shows that percutaneous transluminal angioplasty (PTA) with the sirolimus drug coated balloon (DCB) in patients with femoropopliteal artery disease was/was not noninferior to PTA with the paclitaxel DCB.Prof Ulf Teichgräber joins us onsite at TCT Conference to discuss the findings from the sirolimus- vs. paclitaxel-coated balloon… View more

Intervention

Vascular Disease and Surgery
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 2 years ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
TCT 25: VICTORY Trial: Intravascular Lithotripsy vs Super-High-Pressure Balloons for Calcified Coronary Lesions
Author(s): Matthias Bossard Added: 3 months ago
TCT 2025 - The randomized VICTORY Study finds OCT-guided PCI involving lesion preparation with the OPN super-high-pressure non-compliant balloon is non-inferior to intravascular lithotropsy.Dr Matthias Bossard (Kantonsspital Lucerne, Lucerne, CH) joins us to discuss findings from the VICTORY Trial, a randomized, multicenter, non-inferiority comparison evaluating intravascular lithotripsy versus… View more

Intervention

MI/ACS
LINC 2025: 12-Month Amputation and Readmission Rates from TRUE-PTX
Author(s): Marianne Brodmann Added: 1 year ago
LINC 2025 - 12-month amputation and readmission rates from the TRUE-PTX study suggests endovascular revascularisation for peripheral artery disease (PAD) with drug-eluting devices lead to better outcomes than with bare device therapies.Dr Marianne Brodmann (Medical University of Graz, AT) joins us to discuss the TRUE-PTX study evaluating a database of patients in the US with PAD who have recieved… View more

Intervention

Vascular Disease and Surgery
TCT 25: LIFE-BTK: The Esprit™ BTK Drug-Eluting Resorbable Scaffold for Infrapopliteal Lesions
Author(s): Sahil Parikh Added: 3 months ago
TCT 2025 - Three-year findings from LIFE-BTK show the Esprit™ BTK scaffold is a durable and effective treatment option for patients with CLTI.Dr Sahil Parikh (Columbia University Vagelos College of Physicians & Surgeons, New York, US) joins us to share the three-year findings from LIFE-BTK (NCT04227899). The randomized controlled trial aimed to evaluate the safety and efficacy of the Esprit™ BTK… View more

Intervention

Vascular Disease and Surgery
Balloon Techniques for Coronary Calcification Lesions
Author(s): Max W Maffey , Rodrigo Bagur Added: 1 year ago

Imaging & Diagnostics

Intervention